ELN Home  · 

European LeukemiaNet - Network info and goals

The objective of the European LeukemiaNet is to integrate the leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia-related research and health care and cure.

Achievements of the ELN

Achievements in addition to the integration of leukemia research among its more than 1000 physicians and researchers and 220 institutions are the more than 100 management recommendations and guidelines for all forms of leukemia and related interdisciplinary specialities. A selection of the most recent recommendations (2016-2018) is included in the attachment. We also list the publications by others which carry the European LeukemiaNet in their titles. The key instrument of integration are regular meetings, in particular the annual ELN symposium at no cost for participants.

Achievements ELN 2016-2018.pdf (436KB)

Achievements ELN 2016-2018.pdf

Definition and funding of the European LeukemiaNet

The European LeukemiaNet is a publicly funded research network of excellence. Goal is cure of leukemia by integration of European leukemia research and spread of excellence. The website delivers information for physicians, researchers and the public on the disease, ongoing clinical trials, research projects and organizational matters. You can get information about the European LeukemiaNet in various European languages. The European LeukemiaNet was funded by the 6th Framework Program of the European Community until 2011, by the European Research Foundation until 2015 and is currently funded by the ELN-Foundation.

The European LeukemiaNet is a publicly funded research network of excellence. Goal is cure of leukemia by integration of European leukemia research and spread of excellence. The website delivers information for physicians, patients (e.g. patient organisations in Europe), ongoing clinical trials and further information about the disease. You can get information about the European LeukemiaNet in various european languages. The European LeukemiaNet is funded by the 6th Framework Program of the European Community.

News ELN Recommendations Overview over selected recent ELN recommendations in CANCER March 15, 2018; page 1100-1104 ELN Breakfast Meeting at ASH 2018 San Diego ELN will organize another Breakfast Meeting at ASH with the usual program on December 2, 2018: breakfast 6:00-6:30, Plenary 6:30-7:00, Breakouts 7:00-9:30. Venue to follow ELN Symposium 2019 The next ELN-Symposium will be on February 12, 2019, in Mannheim, Rosengarten Convention Center. Please, mark your calendar. Information Letter no.12 Right in time for the annual symposium, we are pleased to present the 12th Information Letter of the European LeukemiaNet. In this issue: results from the PROMYSE APL registry, new therapies and the role of TP53 alterations in CLL, ELTS-score for CML, the new EU-regulation on clinical trials, MDS-RIGHT, and many more. New Score: EUTOS long-term survival (ELTS) score for CML The new ELTS score allows for the prognosis of long-term survival in adult CML patients. Determine the prognostic risk group using the free online calculator. MDS Pocket Card 2014 Diagnosis and treatment of primary myelodysplastic syndromes (MDS) in adults. Recommendations from the European LeukemiaNet

There are currently no items in Calendar!